Skip to content
zynerba logo
  • Investors
    • IR Information
    • Stock Information
    • Press Releases
    • Events & Webcasts
    • Presentations
    • Enhanced SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Investor FAQs
    • IRS Form 8937
    • Investor Contacts
  • News
    • Press Releases
    • Events
  • Publications
    • Manuscripts and Presentations
  • Careers
  • LinkedIn
  • Twitter
  • Our Focus
    • Why Rare?
    • Why Neuropsychiatric Disorders?
    • Why Cannabinoids?
    • Why pharmaceutical manufacturing?
  • Our Pipeline
    • ZygelTM
    • Early Access to Medicine
  • Clinical Trials
  • Our Team
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Patient Resources
    • FXS
    • ASD
    • 22q

Zynerba Press Releases

24 May 22 Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

17 May 22 Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

16 May 22 Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights

11 May 22 Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting

9 May 22 Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting

2 May 22 Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting

21 Apr 22 Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting

5 Apr 22 Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference

22 Mar 22 Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit

1 Mar 22 Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Page 1 of 20 | 1 2 3 4 5 Next ›Last »

    This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy Notice.

    • Privacy Policy
    • Terms of Use
    • Cookie Notice
    • Accessibility Statement
    • Contact Us

    © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved.

    zynerba inverted logo

    80 W. Lancaster Avenue, Suite 300
    Devon, PA 19333
    484.581.7505